A
Menu
First published September 18, 2025 Application Aachen patent A – Human necessities

MODIFIED PROTEINS

Espacenet Family 91274756

Abstract

A protein is disclosed herein. The protein comprises: (i) a polypeptide having an alpha helical DNA binding domain, wherein the polypeptide has 50 or more amino acid residues, and wherein the alpha helical DNA binding domain comprises a first amino acid and a second amino acid, wherein the second amino acid is non-adjacent to the first amino acid; and (ii) a peptide staple covalently linking a side chain of the first amino acid to a side chain of the second amino acid. Also described is a pharmaceutical composition comprising the protein, as well as methods and uses of the protein dimer. Also described is a method of preparing the protein.

Inventors 2

  1. Sebastian J. Pomplun Aachen author as filed: Pomplun, Sebastian Johannes
  2. Jan Pascal Kahler Aachen author as filed: Kahler, Jan Pascal

Inventors are linked to an Aachen author when surname and first name match exactly one author.

Applicants

Cited papers 14 in the database

Non-patent literature as cited (39)
  • - SAMBROOK, J. ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
  • - KOTEWICZ, M. L. ET AL., NUCL. ACIDS RES., vol. 16, 1988, pages 265
  • - SOLTIS, D. A.SKALKA, A. M., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 3372 - 3376
  • - BROCK, T. D.FREEZE, H., J. BACTERIOL., vol. 98, no. 1, 1969, pages 289 - 297
  • - OSHIMA, T.IMAHORI, K., INT. J. SYST. BACTERIOL., vol. 24, no. 1, 1974, pages 102 - 112
  • - CHUNGMILLER: "Nucleic Acids Res.", vol. 16, 1988, pages: 3580
  • - LEE, T. I.YOUNG, R. A.: "Transcriptional regulation and its misregulation in disease", CELL, vol. 152, 2013, pages 1237 - 1251, XP029001372, DOI: 10.1016/j.cell.2013.02.014
  • - BOIJA, A. ET AL.: "Transcription Factors Activate Genes through the Phase-Separation Capacity of Their Activation Domains", CELL, vol. 175, 2018, pages 1842 - 1855
  • - BUSHWELLER, J. H.: "Targeting transcription factors in cancer - from undruggable to reality", NAT. REV. CANCER, vol. 19, 2019, pages 611 - 624, XP036914510, DOI: 10.1038/s41568-019-0196-7
  • - MEYER, N.PENN, L. Z.: "Reflecting on 25 years with MYC", NAT. REV. CANCER, vol. 8, 2008, pages 976 - 990, XP055562701
  • - MADDEN, S. K.DE ARAUJO, A. D.GERHARDT, M.FAIRLIE, D. P.MASON, J. M.: "Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc", MOL. CANCER, vol. 20, 2021, pages 1 - 18
  • - DAS, S. KLEWIS, B. A.LEVENS, D.: "MYC: a complex problem", TRENDS CELL BIOL., vol. 33, 2023, pages 235 - 246
  • - BLACKWOOD, E. M.EISENMAN, R. N.: "Max: A Helix-Loop-Helix Zipper Protein That Complex with Myc", SCIENCE, vol. 251, 1991, pages 1211 - 1217, XP001030860, DOI: 10.1126/science.2006410
  • - KALKAT, M. ET AL.: "MYC Protein Interactome Profiling Reveals Functionally Distinct Regions that Cooperate to Drive Tumorigenesis", MOL. CELL, vol. 72, 2018, pages 836 - 848
  • - NITHUN, R. V. ET AL.: "Deciphering the Role of the Ser-Phosphorylation Pattern on the DNA-Binding Activity of Max Transcription Factor Using Chemical Protein Synthesis", ANGEW. CHEMIE, vol. 62, 2023
  • - FERRÉ-D'AMARÉ, A. R.PRENDERGAST, G. C.ZIFF, E. B.BURLEY, S. K.: "Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain", NATURE, vol. 363, 1993, pages 38 - 45
  • - NAIR, S. K. & BURLEY, S. K.: "X-ray structures of Myc-Max and Mad-Max recognizing DNA: Molecular bases of regulation by proto-oncogenic transcription factors", CELL, vol. 112, 2003, pages 193 - 205, XP055980573
  • - STRUNTZ, N. B. ET AL.: "Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription", CELL CHEM. BIOL., vol. 26, 2019, pages 711 - 723
  • - BOIKE, L. ET AL.: "Discovery of a Functional Covalent Ligand Targeting an Intrinsically Disordered Cysteine within MYC", CELL CHEM. BIOL., 2020, pages 1 - 10
  • - LI, Z. ET AL., MYC-TARGETING INHIBITORS GENERATED FROM A STEREODIVERSIFIED BICYCLIC PEPTIDE LIBRARY, 2023
  • - SOUCEK, L. ET AL.: "Design and properties of a Myc derivative that efficiently homodimerizes", ONCOGENE, vol. 17, 1998, pages 2463 - 2472, XP037734029, DOI: 10.1038/sj.onc.1202199
  • - JUNG, L. A. ET AL.: "OmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumors", ONCOGENE, vol. 36, 2017, pages 1911 - 1924, XP037653177, DOI: 10.1038/onc.2016.354
  • - LUSTIG, L. C. ET AL.: "Inhibiting MYC binding to the E-box DNA motif by ME47 decreases tumour xenograft growth", ONCOGENE, vol. 36, 2017, pages 6830 - 6837, XP037653056, DOI: 10.1038/onc.2017.275
  • - MONTAGNE, M. ET AL.: "The max b-HLH-LZ can transduce into cells and inhibit c-Myc transcriptional activities", PLOS ONE, vol. 7, 2012, pages 2 - 10
  • - LIN, X.HAREL, O.JBARA, M.: "Chemical Engineering of Artificial Transcription Factors by Orthogonal Palladium(II)-Mediated S-Arylation Reactions", ANGEW. CHEMIE - INT. ED., 2023, pages 202317511
  • - POMPLUN, S. ET AL.: "Parallel Automated Flow Synthesis of Covalent Protein Complexes That Can Inhibit MYC-Driven Transcription", ACS CENT. SCI., vol. 7, 2021, pages 1408 - 1418
  • - JBARA, M. ET AL.: "Engineering Bioactive Dimeric Transcription Factor Analogs via Palladium Rebound Reagents", J. AM. CHEM. SOC., vol. 143, 2021, pages 11788 - 11798, XP055980204, DOI: 10.1021/jacs.1c05666
  • - HAREL, O.JBARA, M.: "Chemical Synthesis of Bioactive Proteins", ANGEW. CHEMIE - INT. ED., vol. 62, 2023
  • - LEADER BBACA Q JGOLAN D E.: "Protein therapeutics: a summary and pharmacological classification", NAT. REV. DRUG DISCOV., vol. 7, 2008, pages 21 - 39, XP037925345, DOI: 10.1038/nrd2399
  • - BEAULIEU, M. E. ET AL.: "Intrinsic cell-penetrating activity propels omomyc from proof of concept to viable anti-myc therapy", SCI. TRANSL. MED., vol. 11, 2019, pages 1 - 14
  • - GARRALDA, E. ET AL.: "MYC targeting by OMO-103 in solid tumors: a phase 1 trial", NAT. MED., 2024
  • - WANG, E. ET AL.: "Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers", ONCOGENE, vol. 38, 2019, pages 140 - 150, XP036667380, DOI: 10.1038/s41388-018-0421-y
  • - SPELTZ, T. E. ET AL.: "Targeting MYC with modular synthetic transcriptional repressors derived from bHLH DNA-binding domains", NAT. BIOTECHNOL., vol. 41, 2023, XP093204422, DOI: 10.1038/s41587-022-01504-x
  • - XIAOXI LIN ET AL: "Chemical Engineering of Artificial Transcription Factors by Orthogonal Palladium(II)-Mediated S-Arylation Reactions", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, VERLAG CHEMIE, HOBOKEN, USA, vol. 63, no. 5, 22 December 2023 (2023-12-22), pages n/a, XP072570930, ISSN: 1433-7851, DOI: 10.1002/ANIE.202317511
  • - JBARA MUHAMMAD ET AL: "Engineering Bioactive Dimeric Transcription Factor Analogs via Palladium Rebound Reagents", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 143, no. 30, 22 July 2021 (2021-07-22), pages 11788 - 11798, XP055980204, ISSN: 0002-7863, DOI: 10.1021/jacs.1c05666
  • - BROWN ZACHARY Z. ET AL: "Multiple Synthetic Routes to the Mini-Protein Omomyc and Coiled-Coil Domain Truncations", THE JOURNAL OF ORGANIC CHEMISTRY, vol. 85, no. 3, 29 October 2019 (2019-10-29), United States, pages 1466 - 1475, XP055980564, ISSN: 0022-3263, DOI: 10.1021/acs.joc.9b02467
  • - AMANDA L. EDWARDS ET AL: "Challenges in Targeting a Basic Helix-Loop-Helix Transcription Factor with Hydrocarbon-Stapled Peptides", ACS CHEMICAL BIOLOGY, vol. 11, no. 11, 19 September 2016 (2016-09-19), pages 3146 - 3153, XP055373864, ISSN: 1554-8929, DOI: 10.1021/acschembio.6b00465
  • - LI XIANG ET AL: "Stapled Helical Peptides Bearing Different Anchoring Residues", CHEMICAL REVIEWS, vol. 120, no. 18, 23 September 2020 (2020-09-23), US, pages 10079 - 10144, XP093123061, ISSN: 0009-2665, DOI: 10.1021/acs.chemrev.0c00532
  • - MOIOLA MATTIA ET AL: "Stapled Peptides-A Useful Improvement for Peptide-Based Drugs", MOLECULES, vol. 24, no. 20, 1 October 2019 (2019-10-01), DE, pages 3654, XP055809453, ISSN: 1433-1373, DOI: 10.3390/molecules24203654

Cited patents 1

US2019135868A1